» Articles » PMID: 31779161

Histamine-Releasing Factor, a New Therapeutic Target in Allergic Diseases

Overview
Journal Cells
Publisher MDPI
Date 2019 Nov 30
PMID 31779161
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Histamine-releasing activities on human basophils have been studied as potential allergy-causing agents for four decades. An IgE-dependent histamine-releasing factor (HRF) was recently shown to interact with a subset of immunoglobulins. Peptides or recombinant proteins that block the interactions between HRF and IgE have emerged as promising anti-allergic therapeutics, as administration of them prevented or ameliorated type 2 inflammation in animal models of allergic diseases such as asthma and food allergy. Basic and clinical studies support the notion that HRF amplifies IgE-mediated activation of mast cells and basophils. We discuss how secreted HRF promotes allergic inflammation in vitro and in vivo complex disease settings.

Citing Articles

Assesment of Salivary and Serum Levels of HBD2 in Patients with Chronic Angioedema.

Strajtenberger M, Lugovic-Mihic L, Stipic-Markovic A, Artukovic M, Glavina A, Pravica N J Clin Med. 2025; 13(24.

PMID: 39768474 PMC: 11728209. DOI: 10.3390/jcm13247552.


Potential of histamine release factor for the utilization as a universal vaccine antigen against poultry red mites, tropical fowl mites, and northern fowl mites.

Win S, Horio F, Sato J, Motai Y, Seo H, Fujisawa S J Vet Med Sci. 2024; 87(1):1-12.

PMID: 39567007 PMC: 11735211. DOI: 10.1292/jvms.24-0186.


The multifaceted potential of as biomarker and therapeutic target.

Miao G, Yang Y, Yang X, Chen D, Liu L, Lei X Heliyon. 2024; 10(19):e38819.

PMID: 39397949 PMC: 11471257. DOI: 10.1016/j.heliyon.2024.e38819.


Identification and characterization of a novel nematode pan allergen (NPA) from Wuchereria bancrofti and their potential role in human filarial tropical pulmonary eosinophilia (TPE).

Katru S, Balakrishnan A, Munirathinam G, Hadadianpour A, Smith S, Kalyanasundaram R PLoS Negl Trop Dis. 2024; 18(2):e0011972.

PMID: 38354188 PMC: 10898765. DOI: 10.1371/journal.pntd.0011972.


Harnessing the value of TCTP in breast cancer treatment resistance: an opportunity for personalized therapy.

Santamaria G, Cioce M, Rizzuto A, Fazio V, Viglietto G, Lucibello M Cancer Drug Resist. 2023; 6(3):447-467.

PMID: 37842235 PMC: 10571059. DOI: 10.20517/cdr.2023.21.


References
1.
Lavoie J, Ormiston M, Perez-Iratxeta C, Courtman D, Jiang B, Ferrer E . Proteomic analysis implicates translationally controlled tumor protein as a novel mediator of occlusive vascular remodeling in pulmonary arterial hypertension. Circulation. 2014; 129(21):2125-35. DOI: 10.1161/CIRCULATIONAHA.114.008777. View

2.
Choi K, Hsu Y . To cease or to proliferate: new insights into TCTP function from a Drosophila study. Cell Adh Migr. 2009; 1(3):129-30. PMC: 2634012. DOI: 10.4161/cam.1.3.4901. View

3.
Kawakami T, Ando T, Kimura M, Wilson B, Kawakami Y . Mast cells in atopic dermatitis. Curr Opin Immunol. 2009; 21(6):666-78. PMC: 2839879. DOI: 10.1016/j.coi.2009.09.006. View

4.
Pinkaew D, Fujise K . Fortilin: A Potential Target for the Prevention and Treatment of Human Diseases. Adv Clin Chem. 2017; 82:265-300. PMC: 6064975. DOI: 10.1016/bs.acc.2017.06.006. View

5.
Kuna P, Reddigari S, Schall T, Rucinski D, Sadick M, Kaplan A . Characterization of the human basophil response to cytokines, growth factors, and histamine releasing factors of the intercrine/chemokine family. J Immunol. 1993; 150(5):1932-43. View